Standard guidelines for treating metastatic prostate cancer are based on conventional imaging (CT/bone scan). The panel argues that PSMA PET-positive biochemical recurrence represents a different, earlier disease state. This necessitates new treatment paradigms, like definitive therapy durations, not covered by current guidelines.

The advent of highly sensitive PSMA PET imaging identifies metastases in many patients previously considered to have only biochemical relapse (BCR). However, experts argue against a knee-jerk reaction to treat. Many of these patients, particularly those with slow PSA doubling times, can be safely observed, challenging the assumption that visible disease always requires immediate intervention.

While PSMA PET scans are more sensitive, they create a clinical dilemma because pivotal trials defining treatment efficacy were based on conventional imaging (CT/bone scans). This forces oncologists to either re-image patients with older technology to match trial criteria or make treatment decisions based on PET data that lacks a clear evidence-based framework for response assessment.

While the landmark EMBARK study enrolled patients with no metastatic disease on conventional imaging (CT/bone scan), a similar population scanned with advanced PSMA PET imaging showed 84% had M1 disease. This suggests that treatments for this population are effective against micrometastases not visible on older scans, blurring the lines between localized and metastatic states.

Early in treatment, tumors are "target-rich" with high PSMA expression, creating an ideal window for radioligand therapy. Citing data from the VISION trial, new clinical trials are being designed to accelerate dosing and intensity upfront to maximize impact, then de-escalate as the target diminishes.

The patient population in pivotal trials like EMBARK, defined as non-metastatic by conventional imaging, is being re-evaluated. A UCLA study showed that over 80% of a similar patient group would have been positive on a PSMA PET scan, suggesting the "M0" classification is largely an artifact of older imaging technology and that these patients likely have micrometastatic disease.

An NCI working group coined "PSMA positive BCR" to classify patients with biochemical relapse (BCR) who have findings on a modern PSMA PET scan. This formally recognizes this group is distinct from both conventionally-defined metastatic patients and traditional BCR patients, necessitating unique clinical trial designs and treatment strategies.

For patients with conventionally negative imaging but positive PSMA PET scans (oligometastatic disease), continuous intensified therapy may be overtreatment. A new paradigm involves metastasis-directed therapy followed by a short course of escalated treatment, then stopping to observe. This "time-limited" approach balances efficacy with reducing long-term treatment burden.

NCCN now recommends PSMA PET as a potential replacement for traditional CT, MRI, and bone scans for initial staging of higher-risk prostate cancer and detecting recurrence. This shift is based on PSMA PET's superior sensitivity and specificity for finding micrometastatic disease, positioning it as a more effective frontline tool.